Current and future approaches for the therapeutic targeting of metastasis (Review)

International Journal of Molecular Medicine

Volumn 18, Issue 6, 2006, Pages 1025-1036

  Germanov, Elitza ^a   Berman, Jason N ^a   Guernsey, Duane L ^a  

^a DALHOUSIE UNIVERSITY   (Canada)

Author keywords

Angiogenesis; Chemokines; G protein coupled receptors; Glycans; Matrix metalloproteinases; Metastasis; Neurotransmitters; Protein tyrosine kinases; Therapeutic targets

Indexed keywords

AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS; ANTINEOPLASTIC AGENT; CHEMOKINE; G PROTEIN COUPLED RECEPTOR; MATRIX METALLOPROTEINASE; POLYSACCHARIDE; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE;

ANIMAL; DRUG ANTAGONISM; DRUG EFFECT; GENETICS; HUMAN; METABOLISM; METASTASIS; NEOPLASM; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS; CHEMOKINES; HUMANS; MATRIX METALLOPROTEINASES; NEOPLASM METASTASIS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; NEUROTRANSMITTER AGENTS; POLYSACCHARIDES; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; RECEPTORS, G-PROTEIN-COUPLED; SIGNAL TRANSDUCTION;

EID: 39049185072     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.18.6.1025     Document Type: Review

References (111)

1. Fidler IJ: The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. Nat Rev Cancer 3: 453-458, 2003.
2. Sierra A: Metastases and their microenvironments: linking pathogenesis and therapy. Drug Resist Updat 8: 247-257, 2005.
3. Papetti M and Herman IM: Mechanisms of normal and tumor-derived angiogenesis. Am J Physiol Cell Physiol 282: 947-970, 2002.
4. Wittekind C and Neid M: Cancer invasion and metastasis. Oncology 69 (Suppl 1): 14-16, 2005.
5. Fuster MM and Esko JD: The sweet and sour of cancer: glycans as novel therapeutic targets. Nat Rev Cancer 5: 526-542, 2005.
6. Entschladen F, Drell TL IV, Lang K, Joseph J and Zaenker KS: Neurotransmitters and chemokines regulate tumor cell migration: potential for a new pharmacological approach to inhibit invasion and metastasis development. Curr Pharm Des 11: 403-411, 2005.
7. Onn A, Tsuboi M and Thatcher N: Treatment of non-small cell lung cancer: a perspective on the recent advances and the experience with gefitinib. Br J Cancer 91 (Suppl 2): S11-S17, 2004.
8. Eccles SA: Targeting key steps in metastatic tumour progression. Curr Opin Genet Dev 15: 77-86, 2005.
9. Traxler P, Bold G, Buchdunger E, et al: Tyrosine kinase inhibitors: from rational design to clinical trials. Med Res Rev 21: 499-512, 2001.
10. Pao W and Miller VA: Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small cell lung cancer: current knowledge and future directions. J Clin Oncol 23: 2556-2568, 2005.
11. Goldman CK, Kim J, Wong WL, King V, Brock T and Gillespie GY: Epidermal growth factor stimulates vascular endothelial growth factor production by human malignant glioma cells: a model of glioblastoma multiforme pathophysiology. Mol Biol Cell 4: 121-133, 1993.
12. Yamanaka Y, Friess H, Kobrin MS, Buchler M, Beger HG and Korc M: Coexpression of epidermal growth factor receptor and ligands in human pancreatic cancer is associated with enhanced tumor aggressiveness. Anticancer Res 13: 565-569, 1993.
13. Silvestri GA and Rivera MP: Targeted therapy for the treatment of advanced non-small cell lung cancer: a review of the epidermal growth factor receptor antagonists. Chest 128: 3975-3984, 2005.
14. Baker CH, Solorzano CC and Fidler IJ: Blockade of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling for therapy of metastatic human pancreatic cancer. Cancer Res 62: 1996-2003, 2002.
15. Kim SJ, Uehara H, Karashima T, Shepherd DL, Killion JJ and Fidler IJ: Blockade of epidermal growth factor receptor signaling in tumor cells and tumor-associated endothelial cells for therapy of androgen-independent human prostate cancer growing in the bone of nude mice. Clin Cancer Res 9: 1200-1210, 2003.
16. Hoekstra R, Dumez H, Eskens FA, et al: Phase I and pharmacologic study of PKI166, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. Clin Cancer Res 11: 6908-6915, 2005.
17. Fukuoka M, Yano S, Giaccone G, et al: Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small cell lung cancer (The IDEAL 1 Trial) corrected. J Clin Oncol 21: 2237-2246, 2003.
18. Kris MG, Natale RB, Herbst RS, et al: Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 290: 2149-2158, 2003.
19. Lynch TJ, Bell DW, Sordella R, et al: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small cell lung cancer to gefitinib. N Engl J Med 350: 2129-2139, 2004.
20. Paez JG, Janne PA, Lee JC, et al: EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304: 1497-1500, 2004.
21. Pao W, Miller V, Zakowski M, et al: EGF receptor gene mutations are common in lung cancers from 'never smokers' and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 101: 13306-13311, 2004.
22. Pao W, Miller VA, Politi KA, et al: Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2: e73, 2005.
23. Cappuzzo F, Hirsch FR, Rossi E, et al: Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-smallcell lung cancer. J Natl Cancer Inst 97: 643-655, 2005. (Pubitemid 40812628)
24. Pao W, Wang TY, Riely GJ, et al: KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med 2: e17, 2005.
25. Romond EH, Perez EA, Bryant J, et al: Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353: 1673-1684, 2005.
26. Safran H, Iannitti D, Ramanathan R, et al: Herceptin and gemcitabine for metastatic pancreatic cancers that overexpress HER-2/neu. Cancer Invest 22: 706-712, 2004.
27. Safran H, Di Petrillo T, Nadeem A, et al: Trastuzumab, paclitaxel, cisplatin, and radiation for adenocarcinoma of the esophagus: a phase I study. Cancer Invest 22: 670-677, 2004.
28. Salesse S and Verfaillie CM: BCR/ABL: from molecular mechanisms of leukemia induction to treatment of chronic myelogenous leukemia. Oncogene 21: 8547-8559, 2002. (Pubitemid 36084187)
29. Branford S, Rudzki Z, Harper A, et al: Imatinib produces significantly superior molecular responses compared to interferon alpha plus cytarabine in patients with newly diagnosed chronic myeloid leukemia in chronic phase. Leukemia 17: 2401-2409, 2003.
30. Chiang KC, Chen TW, Yeh CN, Liu FY, Lee HL and Jan YY: Advanced gastrointestinal stromal tumor patients with complete response after treatment with imatinib mesylate. World J Gastroenterol 12: 2060-2064, 2006.
31. Hampton T: Looking beyond imatinib: next line of targeted drugs for CML shows promise. JAMA 295: 369-370, 2006.
32. Radford IR: Imatinib. Novartis. Curr Opin Investig Drugs 3: 492-499, 2002.
33. Hakomori S: Tumor malignancy defined by aberrant glycosylation and sphingo(glyco)lipid metabolism. Cancer Res 56: 5309-5318, 1996.
34. Iida J, Meijne AM, Knutson JR, Furcht LT and McCarthy JB: Cell surface chondroitin sulfate proteoglycans in tumor cell adhesion, motility and invasion. Semin Cancer Biol 7: 155-162, 1996.
35. Bernfield M, Gotte M, Park PW, Reizes O, Fitzgerald ML, Lincecum J and Zako M: Functions of cell surface heparan sulfate proteoglycans. Annu Rev Biochem 68: 729-777, 1999.
36. Wang L, Fuster M, Sriramarao P and Esko JD: Endothelial heparan sulfate deficiency impairs L-selectin- and chemokine-mediated neutrophil trafficking during inflammatory responses. Nat Immunol 6: 902-910, 2005. (Pubitemid 43090445)
37. Muller A, Homey B, Soto H, Ge N, Catron D, Buchanan ME, McClanahan T, Murphy E, Yuan W, Wagner SN, Barrera JL, Mohar A, Verastegui E and Zlotnik A: Involvement of chemokine receptors in breast cancer metastasis. Nature 410: 50-56, 2001.
38. Goldshmidt O, Zcharia E, Abramovitch R, et al: Cell surface expression and secretion of heparanase markedly promote tumor angiogenesis and metastasis. Proc Natl Acad Sci USA 99: 10031-10036, 2002.
39. Vlodavsky I, Goldshmidt O, Zcharia E, et al: Molecular properties and involvement of heparanase in cancer progression and normal development. Biochimie 83: 831-839, 2001. (Pubitemid 32821249)
40. Maeder T: Sweet medicines. Sci Am 287: 40-47, 2002.
41. Roy M, Reiland J, Murry BP, Chouljenko V, Kousoulas KG and Marchetti D: Antisense-mediated suppression of Heparanase gene inhibits melanoma cell invasion. Neoplasia 7: 253-262, 2005.
42. Holmberg LA and Sandmaier BM: Vaccination with Theratope (STn-KLH) as treatment for breast cancer. Expert Rev Vaccines 3: 655-663, 2004.
43. Holmberg LA, Oparin DV, Gooley T and Sandmaier BM: The role of cancer vaccines following autologous stem cell rescue in breast and ovarian cancer patients: experience with the STn- KLH vaccine (Theratope). Clin Breast Cancer 3 (Suppl 4): S144-S151, 2003.
44. de Kleijn EM and Punt CJ: Biological therapy of colorectal cancer. Eur J Cancer 38: 1016-1022, 2002.
45. Ragupathi G, Livingston PO, Hood C, et al: Consistent antibody response against ganglioside GD2 induced in patients with melanoma by a GD2 lactone-keyhole limpet hemocyanin conjugate vaccine plus immunological adjuvant QS-21. Clin Cancer Res 9: 5214-5220, 2003.
46. Kawano T, Cui J, Koezuka Y, et al: Natural killer-like non-specific tumor cell lysis mediated by specific ligand-activated Valpha14 NKT cells. Proc Natl Acad Sci USA 95: 5690-5693, 1998.
47. Smyth MJ, Crowe NY, Hayakawa Y, Takeda K, Yagita H and Godfrey DI: NKT cells - conductors of tumor immunity? Curr Opin Immunol 14: 165-171, 2002.
48. Smyth MJ, Crowe NY, Pellicci DG, et al: Sequential production of interferon-gamma by NK1.1(+) T cells and natural killer cells is essential for the antimetastatic effect of alpha-galactosylceramide. Blood 99: 1259-1266, 2002.
49. Toura I, Kawano T, Akutsu Y, Nakayama T, Ochiai T and Taniguchi M: Cutting edge: inhibition of experimental tumor metastasis by dendritic cells pulsed with alpha-galactosylceramide. J Immunol 163: 2387-2391, 1999.
50. Akutsu Y, Nakayama T, Harada M, et al: Expansion of lung V alpha 14 NKT cells by administration of alpha-galactosylceramide- pulsed dendritic cells. Jpn J Cancer Res 93: 397-403, 2002.
51. Ishikawa A, Motohashi S, Ishikawa E, et al: A phase I study of alpha-galactosylceramide (KRN7000)-pulsed dendritic cells in patients with advanced and recurrent non-small cell lung cancer. Clin Cancer Res 11: 1910-1917, 2005.
52. Lee CM, Tanaka T, Murai T, et al: Novel chondroitin sulfate-binding cationic liposomes loaded with cisplatin efficiently suppress the local growth and liver metastasis of tumor cells in vivo. Cancer Res 62: 4282-4288, 2002.
53. Bergers G and Benjamin LE: Tumorigenesis and the angiogenic switch. Nat Rev Cancer 3: 401-410, 2003.
54. Hlatky L, Hahnfeldt P and Folkman J: Clinical application of antiangiogenic therapy: microvessel density, what it does and doesn't tell us. J Natl Cancer Inst 94: 883-893, 2002.
55. Kerbel R and Folkman J: Clinical translation of angiogenesis inhibitors. Nat Rev Cancer 2: 727-739, 2002.
56. Ferrara N, Gerber HP and LeCouter J: The biology of VEGF and its receptors. Nat Med 9: 669-676, 2003.
57. Gerber HP, Malik AK, Solar GP, et al: VEGF regulates haematopoietic stem cell survival by an internal autocrine loop mechanism. Nature 417: 954-958, 2002.
58. Bikfalvi A: Recent developments in the inhibition of angiogenesis: examples from studies on platelet factor-4 and the VEGF/VEGFR system. Biochem Pharmacol 68: 1017-1021, 2004.
59. Stern M and Herrmann R: Overview of monoclonal antibodies in cancer therapy: present and promise. Crit Rev Oncol Hematol 54: 11-29, 2005.
60. Hurwitz H, Fehrenbacher L, Novotny W, et al: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350: 2335-2342, 2004.
61. Yang JC, Haworth L, Sherry RM, et al: A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349: 427-434, 2003.
62. Patel PH, Chaganti RS and Motzer RJ: Targeted therapy for metastatic renal cell carcinoma. Br J Cancer 94: 614-619, 2006.
63. Hainsworth JD, Sosman JA, Spigel DR, Edwards DL, Baughman C and Greco A: Treatment of metastatic renal cell carcinoma with a combination of bevacizumab and erlotinib. J Clin Oncol 23: 7889-7896, 2005.
64. Herbst RS, Johnson DH, Mininberg E, et al: Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small cell lung cancer. J Clin Oncol 23: 2544-2555, 2005.
65. Johnson DH, Fehrenbacher L, Novotny WF, et al: Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small cell lung cancer. J Clin Oncol 22: 2184-2191, 2004.
66. Wood JM, Bold G, Buchdunger E, et al: PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res 60: 2178-2189, 2000.
67. Subbaramaiah K and Dannenberg AJ: Cyclooxygenase 2: a molecular target for cancer prevention and treatment. Trends Pharmacol Sci 24: 96-102, 2003.
68. Sheng H, Shao J, Washington MK and DuBois RN: Prostaglandin E2 increases growth and motility of colorectal carcinoma cells. J Biol Chem 276: 18075-18081, 2001.
69. Ben-Av P, Crofford LJ, Wilder RL and Hla T: Induction of vascular endothelial growth factor expression in synovial fibroblasts by prostaglandin E and interleukin-1: a potential mechanism for inflammatory angiogenesis. FEBS Lett 372: 83-87, 1995.
70. Kakiuchi Y, Tsuji S, Tsujii M, et al: Cyclooxygenase-2 activity altered the cell-surface carbohydrate antigens on colon cancer cells and enhanced liver metastasis. Cancer Res 62: 1567-1572, 2002.
71. Kuwano T, Nakao S, Yamamoto H, Tsuneyoshi M, Yamamoto T, Kuwano M and Ono M: Cyclooxygenase 2 is a key enzyme for inflammatory cytokine-induced angiogenesis. FASEB J 18: 300-310, 2004.
72. Tsuji S, Tsujii M, Kawano S and Hori M: Cyclooxygenase-2 upregulation as a perigenetic change in carcinogenesis. J Exp Clin Cancer Res 20: 117-129, 2001.
73. Sano H, Kawahito Y, Wilder RL, et al: Expression of cyclooxygenase- 1 and -2 in human colorectal cancer. Cancer Res 55: 3785-3789, 1995.
74. Murata H, Kawano S, Tsuji S, et al: Cyclooxygenase-2 overexpression enhances lymphatic invasion and metastasis in human gastric carcinoma. Am J Gastroenterol 94: 451-455, 1999.
75. Iniguez MA, Rodriguez A, Volpert OV, Fresno M and Redondo JM: Cyclooxygenase-2: a therapeutic target in angiogenesis. Trends Mol Med 9: 73-78, 2003.
76. Steinbach G, Lynch PM, Phillips RK, et al: The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 342: 1946-1952, 2000.
77. Altorki NK, Keresztes RS, Port JL, et al: Celecoxib, a selective cyclo-oxygenase-2 inhibitor, enhances the response to preoperative paclitaxel and carboplatin in early-stage non-small cell lung cancer. J Clin Oncol 21: 2645-2650, 2003.
78. Bellon G, Martiny L and Robinet A: Matrix metalloproteinases and matrikines in angiogenesis. Crit Rev Oncol Hematol 49: 203-220, 2004.
79. Cao Y, Chen A, An SS, Ji RW, Davidson D and Llinas M: Kringle 5 of plasminogen is a novel inhibitor of endothelial cell growth. J Biol Chem 272: 22924-22928, 1997.
80. Lucas R, Holmgren L, Garcia I, et al: Multiple forms of angiostatin induce apoptosis in endothelial cells. Blood 92: 4730-4741, 1998.
81. O'Reilly MS, Holmgren L, Shing Y, et al: Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 79: 315-328, 1994.
82. Cao Y, O'Reilly MS, Marshall B, Flynn E, Ji RW and Folkman J: Expression of angiostatin cDNA in a murine fibrosarcoma suppresses primary tumor growth and produces long-term dormancy of metastases. J Clin Invest 101: 1055-1063, 1998.
83. Sonveaux P, Brouet A, Havaux X, Gregoire V, Dessy C, Balligand JL and Feron O: Irradiation-induced angiogenesis through the up-regulation of the nitric oxide pathway: implications for tumor radiotherapy. Cancer Res 63: 1012-1019, 2003.
84. Mauceri HJ, Hanna NN, Beckett MA, et al: Combined effects of angiostatin and ionizing radiation in antitumour therapy. Nature 394: 287-291, 1998.
85. Rao JS, Gondi C, Chetty C, Chittivelu S, Joseph PA and Lakka SS: Inhibition of invasion, angiogenesis, tumor growth, and metastasis by adenovirus-mediated transfer of antisense uPAR and MMP-9 in non-small cell lung cancer cells. Mol Cancer Ther 4: 1399-1408, 2005.
86. Sparano JA, Bernardo P, Stephenson P, Gradishar WJ, Ingle JN, Zucker S and Davidson NE: Randomized phase III trial of marimastat versus placebo in patients with metastatic breast cancer who have responding or stable disease after first-line chemotherapy: Eastern Cooperative Oncology Group trial E2196. J Clin Oncol 22: 4683-4690, 2004.
87. Bissett D, O'Byrne KJ, von Pawel J, et al: Phase III study of matrix metalloproteinase inhibitor prinomastat in non-small cell lung cancer. J Clin Oncol 23: 842-849, 2005.
88. Nozaki S, Endo Y, Nakahara H, et al: Inhibition of invasion and metastasis in oral cancer by targeting urokinase-type plasminogen activator receptor. Oral Oncol 41: 971-977, 2005.
89. Martinez-Zaguilan R, Seftor EA, Seftor RE, Chu YW, Gillies RJ and Hendrix MJ: Acidic pH enhances the invasive behavior of human melanoma cells. Clin Exp Metastasis 14: 176-186, 1996.
90. Sennoune SR, Bakunts K, Martinez GM, Chua-Tuan JL, Kebir Y, Attaya MN and Martinez-Zaguilan R: Vacuolar H+-ATPase in human breast cancer cells with distinct metastatic potential: distribution and functional activity. Am J Physiol Cell Physiol 286: C1443-C1452, 2004.
91. Lu X, Qin W, Li J, Tan N, et al: The growth and metastasis of human hepatocellular carcinoma xenografts are inhibited by small interfering RNA targeting to the subunit ATP6L of proton pump. Cancer Res 65: 6843-6849, 2005.
92. Xu L and Fidler IJ: Interleukin 8: an autocrine growth factor for human ovarian cancer. Oncol Res 12: 97-106, 2000.
93. Fukumura D, Xu L, Chen Y, Gohongi T, Seed B and Jain RK: Hypoxia and acidosis independently up-regulate vascular endothelial growth factor transcription in brain tumors in vivo. Cancer Res 61: 6020-6024, 2001.
94. Itoh T, Tanioka M, Yoshida H, Yoshioka T, Nishimoto H and Itohara S: Reduced angiogenesis and tumor progression in gelatinase A-deficient mice. Cancer Res 58: 1048-1051, 1998.
95. Balkwill F: Cancer and the chemokine network. Nat Rev Cancer 4: 540-550, 2004.
96. Tanaka T, Bai Z, Srinoulprasert Y, Yang BG, Hayasaka H and Miyasaka M: Chemokines in tumor progression and metastasis. Cancer Sci 96: 317-322, 2005.
97. Hanahan D and Weinberg RA: The hallmarks of cancer. Cell 100: 57-70, 2000.
98. Balkwill F: The significance of cancer cell expression of the chemokine receptor CXCR4. Semin Cancer Biol 14: 171-179, 2004.
99. Ganju RK, Brubaker SA, Meyer J, Dutt P, Yang Y, Qin S, Newman W and Groopman JE: The alpha-chemokine, stromal cell-derived factor-1alpha, binds to the transmembrane G-protein-coupled CXCR-4 receptor and activates multiple signal transduction pathways. J Biol Chem 273: 23169-23175, 1998.
100. Guleng B, Tateishi K, Ohta M, et al: Blockade of the stromal cell-derived factor-1/CXCR4 axis attenuates in vivo tumor growth by inhibiting angiogenesis in a vascular endothelial growth factor-independent manner. Cancer Res 65: 5864-5871, 2005.
101. Rubin JB, Kung AL, Klein RS, et al: A small-molecule antagonist of CXCR4 inhibits intracranial growth of primary brain tumors. Proc Natl Acad Sci USA 100: 13513-13518, 2003.
102. Wiley HE, Gonzalez EB, Maki W, Wu MT and Hwang ST: Expression of CC chemokine receptor-7 and regional lymph node metastasis of B16 murine melanoma. J Natl Cancer Inst 93: 1638-1643, 2001.
103. Mashino K, Sadanaga N, Yamaguchi H, Tanaka F, Ohta M, Shibuta K, Inoue H and Mori M: Expression of chemokine receptor CCR7 is associated with lymph node metastasis of gastric carcinoma. Cancer Res 62: 2937-2941, 2002.
104. Ding Y, Shimada Y, Maeda M, Kawabe A, Kaganoi J, Komoto I, Hashimoto Y, Miyake M, Hashida H and Imamura M: Association of CC chemokine receptor 7 with lymph node metastasis of esophageal squamous cell carcinoma. Clin Cancer Res 9: 3406-3412, 2003.
105. Tilly BC, Tertoolen LG, Remorie R, Ladoux A, Verlaan I, de Laat SW and Moolenaar WH: Histamine as a growth factor and chemoattractant for human carcinoma and melanoma cells: action through Ca2(+)-mobilizing H1 receptors. J Cell Biol 110: 1211-1215, 1990.
106. Baba K and Yamaguchi O: Effects of bradykinin on cytoplasmic calcium and motility in murine bladder tumor cells. J Urol 165: 259-262, 2001.
107. Andersson OK, Almgren T, Persson B, Samuelsson O, Hedner T and Wilhelmsen L: Survival in treated hypertension: follow up study after two decades. BMJ 317: 167-171, 1998.
108. Joseph J, Niggemann B, Zaenker KS and Entschladen F: The neurotransmitter gamma-aminobutyric acid is an inhibitory regulator for the migration of SW 480 colon carcinoma cells. Cancer Res 62: 6467-6469, 2002.
109. Drell TL IV, Joseph J, Lang K, Niggemann B, Zaenker KS and Entschladen F: Effects of neurotransmitters on the chemokinesis and chemotaxis of MDA-MB-468 human breast carcinoma cells. Breast Cancer Res Treat 80: 63-70, 2003.
110. Kakkar AK: An expanding role for antithrombotic therapy in cancer patients. Cancer Treat Rev 29 (Suppl 2): 23-26, 2003.
111. Hayakawa Y, Rovero S, Forni G and Smyth MJ: Alpha-galactosylceramide (KRN7000) suppression of chemical- and oncogene-dependent carcinogenesis. Proc Natl Acad Sci USA 100: 9464-9469, 2003.